Fig. 1
Kinetic features of SAA measurements. A SAA aggregation curves of 2 samples with 4 replicates each. Samples show a similar average lag phase (30 h and 31 h (light green line)) and the same number of positive replicates (3 of 4) but quite a different second fastest lag phase (TT2, 34 h and 28 h (dashed lines)). B SAA aggregation curves of 2 samples with 4 replicates each. Samples show a similar average lag phase (23 h and 23 h (light green line)) even though the numbers of positive replicates are quite different (4 of 4 and 2 of 4). TT2 better reflects possible differences (19 h and 25 h (dashed lines)). C Principal component analysis of clinical features (green) and kinetic features as obtained at TUD (blue). For each component (PC1-PC5), the loadings for each feature (cos2) are expressed color-coded as indicated by the legend. Features contributing strongly to a component are marked by large and dark circles. Abbreviations: Diagnosis, PD or DLB; AAO, age at onset; duration, disease duration; LEDD, levodopa daily dose; UPDRS-III, Unified Parkinson’s disease rating scale part III (motor); MoCA, Montreal cognitive assessment; CI, cognitive impairment (presence of); TUD, kinetic parameters measured at TUD; N/4, number of positive replicates (out of four); AUC, area under the curve; Imax, maximum fluorescence intensity; LAG, mean lag phase; TT1, fastest lag phase; TT2, second fastest lag phase